In Situ Co-Amorphization of Olanzapine in the Matrix and on the Coat of Pellets.
(co-)amorphous
dissolution testing
in situ (co-)amorphization
olanzapine
pellets
solubility
stability
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
24 Nov 2022
24 Nov 2022
Historique:
received:
18
10
2022
revised:
18
11
2022
accepted:
22
11
2022
entrez:
23
12
2022
pubmed:
24
12
2022
medline:
24
12
2022
Statut:
epublish
Résumé
In situ amorphization is a promising approach, considered in the present work, to enhance the solubility and dissolution rate of olanzapine, while minimizing the exposure of the amorphous material to the stress conditions applied during conventional processing. The production of pellets by extrusion/spheronization and the coating of inert beads were investigated as novel methods to promote the co-amorphization of olanzapine, a poorly water-soluble drug, and saccharin. Samples were characterized using differential scanning calorimetry, X-ray powder diffraction, Fourier-transform infrared spectroscopy and scanning electron microscopy, and dissolution and stability testing. The co-amorphous produced were compared with crystalline olanzapine, or physical mixture of olanzapine and saccharin. Results suggested that the addition of water to mixtures containing olanzapine and saccharin during the production of pellets, and the coating of inert beads, induced the in situ co-amorphization of these substances. The coating of inert beads enhanced the solubility and dissolution rate of olanzapine, especially when compared to pellets coated with the crystalline drug, but also with pellets containing the co-amorphous entity in the matrix of beads. Nine months stability tests (23 °C/60% RH) confirmed the preservation of the solid-state properties of the co-amorphous form on/in pellets. Overall, results highlighted the feasibility and benefits of in situ co-amorphization, either when the drug was entrapped in the pellets matrix, or preferentially applied directly on the surface of pellets.
Identifiants
pubmed: 36559080
pii: pharmaceutics14122587
doi: 10.3390/pharmaceutics14122587
pmc: PMC9783598
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Fundação para a Ciência e Tecnologia
ID : PTDC/CTM-BIO/3946/2014 and SFRH/BD/137080/2018
Références
Pharmaceutics. 2021 Aug 23;13(8):
pubmed: 34452279
J Pharm Pharmacol. 2011 Apr;63(4):483-90
pubmed: 21401599
J Pharm Sci. 2016 Sep;105(9):2982-2988
pubmed: 27290626
ChemistryOpen. 2021 Dec;10(12):1260-1268
pubmed: 34921592
Eur J Pharm Biopharm. 2018 Dec;133:151-160
pubmed: 30339888
Pharmaceutics. 2020 Jul 11;12(7):
pubmed: 32664477
Expert Opin Drug Deliv. 2020 Oct;17(10):1411-1435
pubmed: 32683996
Ther Adv Psychopharmacol. 2014 Feb;4(1):30-6
pubmed: 24490028
Int J Pharm. 2020 Oct 15;588:119716
pubmed: 32758593
Pharmaceutics. 2018 Jul 19;10(3):
pubmed: 30029516
Adv Drug Deliv Rev. 2016 May 1;100:116-25
pubmed: 26805787
Indian J Pharm Sci. 2008 Mar-Apr;70(2):251-5
pubmed: 20046726
Int J Pharm. 2018 Jan 15;535(1-2):86-94
pubmed: 29102703
Sci Rep. 2020 Oct 28;10(1):18535
pubmed: 33116200
Int J Pharm. 2017 Mar 15;519(1-2):343-351
pubmed: 28115260
Eur J Pharm Biopharm. 2015 Oct;96:44-52
pubmed: 26197392
Int J Pharm. 2005 Sep 14;301(1-2):33-40
pubmed: 16040214
Pharm Res. 2008 Mar;25(3):530-41
pubmed: 17703346
Mol Pharm. 2015 Jan 5;12(1):253-63
pubmed: 25438193
Int J Pharm. 2021 Sep 5;606:120894
pubmed: 34280485
Eur J Pharm Sci. 2014 Oct 1;62:132-40
pubmed: 24907679
RSC Adv. 2019 Jan 29;9(7):3946-3955
pubmed: 35518078
Pharmaceutics. 2021 Mar 15;13(3):
pubmed: 33804159
J Pharm Sci. 2010 Oct;99(10):4251-60
pubmed: 20737632
Pharmaceutics. 2022 Jul 23;14(8):
pubmed: 35893791
Int J Mol Sci. 2022 Sep 06;23(18):
pubmed: 36142179
J Pharm Sci. 2022 Dec;111(12):3327-3339
pubmed: 36007560
Mol Pharm. 2019 Feb 4;16(2):825-833
pubmed: 30575400
J Pharm Pharmacol. 2016 May;68(5):615-24
pubmed: 26245703
Eur J Pharm Biopharm. 2013 Nov;85(3 Pt B):873-81
pubmed: 23537574
Int J Pharm. 2019 Mar 10;558:357-366
pubmed: 30641182
J Drug Deliv Sci Technol. 2021 Feb;61:
pubmed: 33717230
Int J Pharm. 2013 Jun 25;450(1-2):290-5
pubmed: 23612357
Int J Pharm. 2016 Dec 30;515(1-2):403-415
pubmed: 27771485
J Pharm Sci. 2017 Jan;106(1):302-312
pubmed: 27817830